Loading clinical trials...
Loading clinical trials...
Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Conditions
Interventions
Daridorexant 10 mg
Daridorexant 25 mg
+2 more
Locations
106
United States
Pulmonary Associates of the Southeast/WCR
Birmingham, Alabama, United States
Pulmonary Associates, Pa
Glendale, Arizona, United States
Noble Clinical Research
Tucson, Arizona, United States
Preferred Research Partners, Inc
Little Rock, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Core Healthcare Group
Cerritos, California, United States
Start Date
October 9, 2018
Primary Completion Date
February 22, 2021
Completion Date
February 22, 2021
Last Updated
March 2, 2022
NCT05780177
NCT06779149
NCT07028697
NCT07337369
NCT06955299
NCT04573725
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions